Recombinant Mouse Prostacyclin synthase (Ptgis)

What is Prostacyclin Synthase and its role in prostaglandin metabolism?

Prostacyclin synthase (Ptgis) is an enzyme responsible for the conversion of prostaglandin H2 (PGH2) to prostaglandin I2 (also known as prostacyclin). It functions downstream of cyclooxygenases (COX1 and COX2) in the arachidonic acid metabolism pathway. The enzyme catalyzes the final step in prostacyclin biosynthesis, which plays critical roles in vasodilation, inhibition of platelet aggregation, and modulation of inflammatory responses.

In experimental studies, the enzyme has been shown to have a molecular weight of approximately 52 kDa, as confirmed by Western blot analysis using purified bovine enzyme as a positive control . Unlike cyclooxygenase-2 (COX2), which is highly inducible, prostacyclin synthase tends to be constitutively expressed in many cell types, including human mesangial cells, as evidenced by both protein and mRNA expression patterns .

How is Ptgis expression regulated in different tissue types?

Prostacyclin synthase expression demonstrates tissue-specific regulation patterns. In human endothelial cells, while biosynthesis of prostacyclin is primarily controlled through the induction of cyclooxygenase by growth factors or mitogens, the expression of PGIS itself typically remains unchanged . This suggests a constitutive expression pattern for the enzyme in vascular endothelial tissue.

In human mesangial cells, PGIS also exhibits constitutive expression. RT-PCR and Western blot analyses have confirmed that unlike COX2, which shows marked induction upon cytokine stimulation, both PGIS and COX1 mRNA and protein expression remain relatively stable upon exposure to inflammatory cytokines such as IL-1β, TNFα, and IFN-γ . This constitutive nature suggests that regulation of prostacyclin production in these cells occurs primarily through changes in upstream enzymes rather than alterations in PGIS levels.

What experimental models have been developed to study Ptgis function?

Several experimental models have been developed to study Ptgis function, with transgenic mouse models being particularly informative. Researchers have created transgenic FVB/N mice with lung-specific prostacyclin synthase overexpression using a construct consisting of the human SP-C promoter and full-length rat prostacyclin synthase cDNA . The SP-C promoter allows targeted expression to alveolar and airway epithelial cells. These transgenic mice exhibit more than 250% increase in lung 6-keto prostaglandin F1α (the stable metabolite of prostacyclin) compared with their transgene-negative littermates .

These transgenic models have been combined with various cancer induction protocols, including:

• Chemical carcinogenesis models using urethane or MCA/BHT

• Tobacco smoke exposure models with 22-week exposure to cigarette smoke followed by 20 weeks of ambient air

• Orthotopic immunocompetent mouse models using injection of murine lung cancer cell lines such as CMT167 and Lewis Lung Carcinoma (LLC)

These models allow researchers to investigate the effects of altered prostacyclin levels on tumor development, progression, and the underlying molecular mechanisms.

How do you effectively overexpress Ptgis in mouse models for cancer research?

Effective overexpression of Ptgis in mouse models for cancer research requires careful genetic engineering and validation. Based on the documented approaches, the following methodology has been established:

• Construct Development: Create a genetic construct consisting of the human SP-C promoter fused to full-length rat prostacyclin synthase cDNA. The SP-C promoter is critical as it targets expression specifically to alveolar and airway epithelial cells .

• Transgenic Development: Inject the construct into fertilized mouse eggs, transfer to pseudopregnant females, and identify founders by PCR-based genotyping using DNA isolated from tail biopsies .

• Line Propagation: Maintain transgenic lines as heterozygotes by breeding transgenic mice with wild-type mice (typically FVB/N strain) to produce experimental transgenic-positive (Tg+) mice and transgenic-negative (Tg-) littermates as controls .

• Expression Validation: Quantify prostacyclin synthase overexpression through multiple methods:

  • Western blot analysis using specific antibodies against prostacyclin synthase

  • Measurement of prostacyclin metabolites (6-keto-PGF1α) in lung tissue or bronchoalveolar lavage fluid

  • Microarray or RT-PCR analysis to confirm increased PGIS gene expression (research has shown approximately 13-fold increase in mRNA expression in transgenic animals)

• Functional Validation: Assess the biological impact of overexpression by measuring prostaglandin levels, particularly the elevated prostacyclin (PGI2) and decreased prostaglandin E2 (PGE2) levels that should result from the genetic modification .

What methods are used to identify protein interactions with Ptgis?

Several sophisticated methodologies have been employed to identify and characterize protein interactions with prostacyclin synthase:

• Direct Molecular Fishing: This approach combines paramagnetic nanoparticle technology, affinity chromatography, and LC/MS-MS to isolate and identify protein partners from tissue lysates . The technique involves immobilizing purified recombinant prostacyclin synthase on a solid support and passing tissue lysates over this support to capture interacting proteins.

• Size Exclusion Chromatography (SEC): Used in combination with direct molecular fishing to separate protein complexes based on their molecular weights, allowing for the isolation of specific PGIS-protein partner complexes .

• Surface Plasmon Resonance (SPR): This optical biosensor technique provides real-time measurement of binding interactions between immobilized PGIS and potential protein partners. Sample preparation for SPR experiments typically involves careful pH manipulation to optimize binding conditions - for example, tissue lysates may be temporarily acidified (pH 2.0) and then rapidly restored to physiological pH (7.4) before analysis .

• Mass Spectrometry Identification: Following isolation, interacting proteins are identified using high-resolution mass spectrometry techniques. This has led to the discovery of several PGIS-binding proteins involved in various cellular processes .

• Synthetic Peptide Binding Assays: PGIS has been shown to bind synthetic peptides corresponding to sequences of proteins such as GSTA1, GSTM1, aldo-keto reductase (AKR1A1), glutaredoxin 3 (GLRX3), and histidine triad nucleotide binding protein 2 (HINT2) .

These methodologies have revealed potential functional interactions between PGIS and proteins involved in iron and heme metabolism, oxidative stress management, xenobiotic metabolism, and glutathione and prostaglandin pathways.

How does Ptgis overexpression affect gene expression profiles in lung tissue?

Ptgis overexpression leads to significant alterations in gene expression profiles in lung tissue, particularly in type II pneumocytes. Microarray analysis of RNA isolated from these cells has identified distinct gene expression patterns that differentiate transgenic prostacyclin synthase overexpressors from wild-type mice.

Key gene expression changes observed include:

• Antioxidation Pathways: Altered expression of genes involved in managing oxidative stress, which may contribute to the cancer preventive effects of PGIS overexpression .

• Cytochrome P450 Expression: Decreased expression of cytochrome p450 2e1 in transgenic animals, confirmed by both microarray analysis and Western blot validation. This reduction may affect xenobiotic metabolism in the lung .

• Immune Response Genes: Modifications in genes controlling immune function, potentially contributing to enhanced immunosurveillance of developing tumors .

• Cytokine Activity: Changes in genes regulating cytokine production and signaling. In particular, increased expression of CXCL9 has been observed in certain tumor models, which correlates with increased CD4+ tumor-infiltrating lymphocytes .

• Cell Cycle Control: Alterations in genes regulating cell proliferation and apoptosis, which may directly impact tumor development .

Additionally, in the context of orthotopic lung tumor models, PGIS overexpression affects the gene expression profile of the tumor cells themselves, with differential effects depending on the tumor cell type. For instance, CMT167 cells, but not LLC cells, were found to express MHC class II genes and cofactors necessary for MHC class II processing and presentation when recovered from tumor-bearing mice with PGIS overexpression .

What is the evidence that Ptgis overexpression prevents lung carcinogenesis?

Substantial evidence supports the role of Ptgis overexpression in preventing lung carcinogenesis across multiple experimental models:

• Tobacco Smoke Exposure Model: Transgenic mice with lung-specific prostacyclin synthase overexpression exposed to mainstream cigarette smoke for 22 weeks and then held in ambient air for an additional 20 weeks showed significant tumor prevention. Specifically:

  • Tumor incidence was reduced from 84% (16/19) in wild-type mice to 40% (6/15) in transgenic animals (p = 0.012)

  • Tumor multiplicity decreased from 1.2 ± 0.86 tumors/mouse in wild-type to 0.4 ± 0.5 tumors/mouse in transgenic animals (p < 0.001)

• Chemically-Induced Carcinogenesis: Previous studies have demonstrated that PGIS overexpression also reduces lung tumor formation in models using chemical carcinogens such as urethane .

• Mechanism Investigation: At the time of sacrifice, transgenic animals showed significantly elevated prostacyclin (PGI2) levels coupled with decreased prostaglandin E2 (PGE2) levels (2.73 ± 1.76 versus 9.32 ± 1.57 ng/g protein; p = 0.0266) . This altered prostaglandin profile may contribute to the chemopreventive effect.

• Gene Expression Analysis: Western blot analysis confirmed both increased prostacyclin synthase expression and decreased cytochrome p450 2e1 expression in transgenic animals, suggesting potential mechanisms for the observed chemoprevention .

These findings consistently demonstrate that targeted manipulation of prostaglandin production distal to cyclooxygenase significantly reduces lung carcinogenesis, with alterations in antioxidation, immune response, and cytokine pathways likely contributing to this effect.

How does Ptgis overexpression affect tumor progression in established cancer models?

Ptgis overexpression shows differential effects on tumor progression in established cancer models, with efficacy varying based on the tumor cell type and related immunological factors:

• CMT167 Tumor Model: Pulmonary PGIS overexpression significantly inhibited CMT167 lung tumor growth in an orthotopic immunocompetent mouse model. This inhibition was associated with:

  • Increased expression of CXCL9, a chemokine involved in T cell recruitment

  • Increased infiltration of CD4+ T lymphocytes into the tumor microenvironment

  • Abolishment of the tumor-inhibitory effect when CD4+ T cells were immunodepleted, indicating an immune-mediated mechanism

• Lewis Lung Carcinoma (LLC) Model: In contrast to the CMT167 model, pulmonary PGIS overexpression failed to inhibit growth of LLC cells in the same orthotopic model. This differential response was characterized by:

  • No increase in CXCL9 expression in LLC tumors

  • No increase in CD4+ T lymphocyte infiltration

  • Differential gene expression profiles when tumor cells were recovered from mice

• Molecular Basis for Differential Response: Transcriptome profiling revealed that CMT167 cells, but not LLC cells, express MHC class II genes and cofactors necessary for MHC class II processing and presentation when grown in vivo. This suggests that MHC Class II expression by lung cancer cells may represent a biomarker for response to prostacyclin .

These findings demonstrate that prostacyclin can inhibit lung cancer progression in certain contexts, suggesting that prostacyclin analogs may serve as novel immunomodulatory agents in a subset of lung cancer patients, particularly those whose tumors express MHC Class II.

What are the proposed mechanisms by which Ptgis affects tumor development?

Research has identified multiple mechanisms by which Ptgis affects tumor development, encompassing both direct effects on tumor cells and modulation of the tumor microenvironment:

• Altered Prostaglandin Balance: Ptgis overexpression leads to increased production of prostacyclin (PGI2) coupled with decreased levels of prostaglandin E2 (PGE2) . Elevated PGE2 is associated with decreased immune surveillance of tumors and has been implicated in various epithelial cancers. The shift in prostaglandin balance may therefore enhance anti-tumor immune responses.

• Immunomodulatory Effects:

  • Increased expression of CXCL9, a chemokine that attracts T lymphocytes

  • Enhanced infiltration of CD4+ T cells into tumors, as demonstrated in the CMT167 model

  • Dependency on CD4+ T cells for the tumor inhibitory effect, as shown by CD4+ T cell depletion experiments

• Altered Gene Expression in Host Tissue:

  • Changes in antioxidation pathways that may reduce DNA damage from reactive oxygen species

  • Modulation of immune response genes facilitating tumor rejection

  • Alterations in cytokine activity affecting tumor-promoting inflammation

  • Changes in cell cycle control genes potentially limiting proliferative capacity

• Reduced Expression of Xenobiotic Metabolizing Enzymes:

  • Decreased expression of cytochrome p450 2e1, which may reduce activation of procarcinogens in tobacco smoke or other environmental exposures

• Enhanced Antigen Presentation:

  • Response to PGIS overexpression correlates with expression of MHC class II genes by tumor cells, suggesting enhanced antigen presentation may play a role in tumor rejection

These mechanistic insights suggest that Ptgis overexpression creates an unfavorable environment for tumor development through multiple complementary pathways, with particular emphasis on enhancing immunosurveillance of developing tumors.

What are the challenges in measuring prostacyclin production in experimental systems?

Measuring prostacyclin production in experimental systems presents several methodological challenges that researchers must address:

• Rapid Degradation: Prostacyclin (PGI2) is inherently unstable with a half-life of approximately 30 seconds at physiological pH and temperature. It rapidly hydrolyzes to form 6-keto-prostaglandin F1α, necessitating the measurement of this stable metabolite rather than prostacyclin itself .

• Assay Selection: Several methods exist for prostacyclin quantification:

  • Enzyme immunoassay (EIA) for 6-keto-PGF1α

  • Liquid chromatography-mass spectrometry (LC-MS) methods

  • Radioimmunoassay techniques
    Each has different sensitivity, specificity, and technical requirements.

• Sample Collection and Processing: Proper timing and handling of samples is critical. In studies of human mesangial cells, researchers have established protocols for collection of cell culture supernatants with immediate processing or storage at -80°C to prevent degradation .

• Normalization Standards: Expression of results requires appropriate normalization. In the literature, prostacyclin levels have been reported as:

  • ng/g protein for tissue samples

  • pg/mL for cell culture supernatants

  • ng/mg creatinine for urine samples

• Cross-Reactivity: Immunoassay-based methods may suffer from cross-reactivity with other structurally similar prostaglandins, necessitating validation with alternative techniques.

• Basal vs. Stimulated Production: Distinguishing between basal and stimulated prostacyclin production requires careful experimental design. Studies in human mesangial cells have demonstrated significantly increased prostacyclin production (24-fold) following cytokine stimulation, despite unchanged PGIS expression, highlighting the importance of upstream enzyme regulation .

• Tissue Heterogeneity: In complex tissues like lung, different cell types may contribute differentially to prostacyclin production. Some researchers have addressed this by isolating specific cell populations (e.g., type II pneumocytes) for more precise measurement .

How can researchers effectively isolate and analyze Ptgis protein interactions?

Effective isolation and analysis of Ptgis protein interactions requires sophisticated methodological approaches:

• Direct Molecular Fishing with Size Exclusion Chromatography:

  • Immobilize highly purified recombinant PGIS on appropriate matrices

  • Incubate with tissue lysates under physiological conditions

  • Wash to remove non-specifically bound proteins

  • Elute bound proteins and separate by size exclusion chromatography

  • Identify interacting proteins by LC-MS/MS analysis

• Sample Preparation Protocol for Surface Plasmon Resonance:

  • Maintain samples on ice throughout preparation

  • Add 100 μL of 100 mM HCl to 90 μL of 2× buffer A and 10 μL of tissue lysate (4 mg/mL of total protein)

  • Shift pH from 7.4 to 2.0 and incubate on ice for 1 minute

  • Add 30 μL of NaOH solution (~300 mM) to restore pH to 7.4

  • Add 170 μL of 2× buffer B with protease inhibitor cocktail to a final sample volume of 400 μL

  • This pH shift protocol has been shown to effectively preserve protein-protein interactions for SPR analysis

• Validation of Protein Interactions:

  • Confirmation with reciprocal co-immunoprecipitation experiments

  • Surface plasmon resonance analysis with purified proteins

  • Binding assays with synthetic peptides corresponding to sequences of putative protein partners

  • Functional assays to assess the biological relevance of identified interactions

• Bioinformatic Analysis:

  • Classification of interacting proteins into functional categories

  • Pathway analysis to identify enriched biological processes

  • Construction of protein-protein interaction networks

  • Identification of hub proteins that may coordinate multiple interactions

These methodologies have successfully identified novel protein partners for PGIS involved in diverse cellular processes, including iron and heme metabolism, oxidative stress, xenobiotic metabolism, and glutathione and prostaglandin metabolism .

What are the appropriate controls for Ptgis overexpression studies?

Establishing appropriate controls for Ptgis overexpression studies is crucial for ensuring the validity and interpretability of research findings:

• Genetic Controls:

  • Transgene-negative littermates (Tg-) serve as the optimal genetic control for transgenic mice (Tg+)

  • Wild-type FVB/N mice (or other appropriate strain) should be maintained alongside transgenic lines

  • Heterozygous breeding schemes are recommended to produce experimental Tg+ mice and Tg- littermate controls within the same litters

• Transgene Expression Validation:

  • Genotyping by PCR on genomic DNA isolated from tails to confirm transgene presence

  • Quantification of prostacyclin synthase expression by:

    • Western blot analysis with specific antibodies

    • RT-PCR for mRNA levels

    • Microarray analysis (which has shown approximately 13-fold increase in prostacyclin synthase gene expression in transgenic animals)

• Functional Validation:

  • Measurement of downstream metabolites, particularly 6-keto-PGF1α levels in lung tissue or bronchoalveolar lavage fluid

  • Comparison of PGE2 levels between transgenic and wild-type animals

  • Assessment of other prostaglandins to evaluate pathway shifts

• Experimental Model Controls:

  • In tobacco smoke exposure models, both transgenic and control mice should receive identical smoke exposure protocols (e.g., 22 weeks exposure followed by 20 weeks ambient air)

  • In orthotopic tumor models, both groups should receive identical tumor cell injections with accurate cell counting prior to injection

  • For immunodepletion experiments, isotype-matched antibody controls should be used alongside specific depleting antibodies

• Tissue-Specific Effects:

  • Analysis should include examination of tissues not targeted by the promoter (e.g., non-lung tissues in SP-C promoter-driven transgenic models) to confirm tissue specificity

  • Isolation of specific cell types (e.g., type II pneumocytes) for targeted analysis

By implementing these comprehensive controls, researchers can confidently attribute observed phenotypes to Ptgis overexpression rather than to experimental artifacts or confounding factors.

What are potential biomarkers for predicting response to Ptgis-based therapies?

Research has identified several potential biomarkers that may predict response to Ptgis-based therapies, warranting further investigation:

• MHC Class II Expression:

  • Studies in orthotopic lung tumor models revealed that tumors expressing MHC class II genes and cofactors necessary for antigen processing and presentation (like CMT167 cells) responded to prostacyclin overexpression, while those lacking this expression (LLC cells) did not

  • This suggests that assessment of MHC Class II expression in tumors might serve as a predictive biomarker for response to prostacyclin analogs in clinical settings

• Prostanoid Production Profile:

  • The baseline ratio of PGI2 to PGE2 may predict therapeutic response

  • Studies have consistently shown that Ptgis overexpression not only increases prostacyclin levels but also decreases PGE2 levels

  • Measurement of urinary or plasma metabolites of these prostanoids could potentially serve as non-invasive biomarkers

• Inflammatory Gene Signature:

  • Gene expression analysis has identified alterations in immune response and cytokine activity genes in response to Ptgis overexpression

  • Development of an inflammatory gene signature from tumor biopsies might help identify patients likely to benefit from prostacyclin-based interventions

• Tumor-Infiltrating Lymphocytes:

  • The presence and composition of tumor-infiltrating lymphocytes, particularly CD4+ T cells, correlates with response to Ptgis overexpression in certain tumor models

  • Immunohistochemical assessment of CD4+ T cell infiltration could serve as a companion diagnostic

• CXCL9 Expression:

  • Increased CXCL9 expression was associated with successful tumor inhibition by prostacyclin overexpression

  • Measurement of CXCL9 levels in tumor tissue or potentially in circulation could help predict therapeutic efficacy

These potential biomarkers require validation in larger preclinical studies and eventually in clinical trials of prostacyclin analogs, but they provide promising avenues for developing companion diagnostics to identify patients most likely to benefit from such therapies.

How might Ptgis-targeted therapies be combined with immunotherapy approaches?

The immunomodulatory effects of Ptgis suggest several promising strategies for combining Ptgis-targeted therapies with current immunotherapy approaches:

• Combination with Immune Checkpoint Inhibitors:

  • Prostacyclin's ability to increase CD4+ T cell infiltration into tumors could potentially enhance the efficacy of PD-1/PD-L1 blockade

  • By modulating the tumor microenvironment, prostacyclin analogs might convert "cold" tumors (lacking immune infiltration) to "hot" tumors more responsive to checkpoint inhibition

  • This approach might be particularly effective in tumors expressing MHC Class II, where prostacyclin has demonstrated immunomodulatory effects

• Enhancement of Antigen Presentation:

  • The association between prostacyclin efficacy and MHC Class II expression suggests a role in antigen presentation

  • Prostacyclin analogs might be combined with cancer vaccines or adoptive T cell therapies to enhance presentation of tumor antigens and subsequent T cell activation

• Modulation of Inflammatory Signaling:

  • Prostacyclin alters the prostaglandin balance by increasing PGI2 and decreasing PGE2 levels

  • This shift in inflammatory signaling could potentially mitigate immunosuppressive effects of PGE2 in the tumor microenvironment

  • Combining prostacyclin analogs with COX-2 inhibitors might provide complementary targeting of the prostaglandin pathway

• Sequence and Timing Considerations:

  • Prostacyclin analogs might be effective when administered prior to immunotherapy to create a more favorable immune microenvironment

  • Alternatively, they might enhance the durability of response when administered following initial immunotherapy

• Biomarker-Guided Combination Strategies:

  • Selection of appropriate combinations could be guided by the proposed biomarkers such as MHC Class II expression, CXCL9 levels, or tumor-infiltrating lymphocyte profiles

  • This personalized approach would maximize therapeutic benefit while minimizing unnecessary treatments

These combination strategies represent promising avenues for future research, potentially expanding the reach of immunotherapy to patient populations currently refractory to single-agent approaches.

What transgenic models could advance our understanding of Ptgis biology?

Development of novel transgenic models would significantly advance our understanding of Ptgis biology and its therapeutic implications:

• Conditional and Inducible Ptgis Expression Systems:

  • Cre-loxP systems allowing tissue-specific and temporally controlled Ptgis expression

  • Tet-on/Tet-off systems enabling reversible Ptgis overexpression to distinguish between developmental and acute effects

  • These systems would help determine the optimal timing for prostacyclin-based interventions and elucidate stage-specific effects in cancer progression

• Cell Type-Specific Ptgis Modulation:

  • Beyond the lung epithelial-specific models (using SP-C promoter) , development of models targeting Ptgis expression in:

    • Endothelial cells (using Tie2 or VE-cadherin promoters)

    • Immune cells (using CD45 or lineage-specific promoters)

    • Fibroblasts (using FSP1 or α-SMA promoters)

  • These models would clarify the contribution of different cellular sources of prostacyclin to tumor development and progression

• Ptgis Knockout Models with Reconstitution:

  • Complete or conditional Ptgis knockout models

  • Rescue experiments with cell type-specific reconstitution

  • These approaches would define the essential sources of prostacyclin for tumor inhibition

• Dual Transgenic Systems:

  • Combine Ptgis overexpression with modifications to other prostaglandin pathway components (COX-2, mPGES-1, etc.)

  • Create dual reporter systems tracking both Ptgis expression and functional outcomes (e.g., immune cell infiltration)

  • These models would elucidate pathway interactions and compensatory mechanisms

• Humanized Mouse Models:

  • Incorporate human Ptgis into immunodeficient mice reconstituted with human immune systems

  • These models would better recapitulate human biology and immune responses to prostacyclin modulation

• CRISPR-Engineered Ptgis Variants:

  • Generate mice expressing Ptgis variants with altered catalytic activity or protein interaction domains

  • These precision modifications would help distinguish enzymatic from non-enzymatic functions of Ptgis

These advanced transgenic models would provide more nuanced insights into Ptgis biology across different tissues, cell types, and disease states, ultimately informing the development of more targeted therapeutic approaches.